TITLE:
Viracept Expanded Access Program

CONDITION:
HIV Infections

INTERVENTION:
Nelfinavir mesylate

SUMMARY:

      To make nelfinavir mesylate (Viracept) available for treatment of HIV positive patients who
      are unable to take the three commercially available protease inhibitors (because of failure,
      intolerance, or contraindication) and who have a CD4 cell count of <= 50. To obtain
      additional information on the safety profile of nelfinavir mesylate (Viracept).

      (PER AMENDMENT 1/8/97: People now qualify for the Viracept Program if they are unable to
      take indinavir and/or ritonavir due to intolerance, contraindication or prior failure.)
    

DETAILED DESCRIPTION:
NONE

ELIGIBILITY:
Gender: All
Age: 13 Years to N/A
Criteria:

        Inclusion Criteria

        Patients must have:

          -  HIV infection.

          -  CD4 T cell count <= 100 cells/mm3.

          -  Failed, been intolerant of or had a contraindication to all three commercially
             available protease inhibitors (saquinavir, indinavir and ritonavir).

        (PER AMENDMENT 1/8/97:

          -  People now qualify for the Viracept Program if they are unable to take indinavir
             and/or ritonavir due to intolerance, contraindication or prior failure.)

        Exclusion Criteria

        Prior Medication:

        Excluded:

        Prior therapy with Viracept.

        Required:

          -  Indinavir.

          -  Saquinavir.

          -  Ritonavir.
      
